Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Feature|Videos|February 11, 2026
ROIS CDMO: A New Brand, a Bold Acquisition, and a Global CDMO Vision for Next-Generation Injectables
Key Takeaways
- Understand how ROIS’s new brand reflects its evolution into a tier-1 global CDMO for high-value injectables.
- Learn why the Phoenix, Arizona acquisition is a strategic milestone, expanding US presence, capacity, and high-potent/lyophilization capabilities.
Hear from Miguel Ángel Ortega Sánchez, Corporate Industrial Director at ROIS CDMO, as he breaks down the company’s new brand, a strategic acquisition, and what these moves mean for ROIS’s future as a global leader in high-value injectables.
Sponsored by ROIS CDMO
In this interview, Miguel Ángel Ortega Sánchez, Corporate Industrial Director at ROIS CDMO, explains how the company’s new brand identity marks its evolution into a tier-1 global CDMO specializing in high-value injectables. The rebrand reflects ROIS’s commitment to scale, invest, and operate as a dedicated partner for sterile and high-potent drug development and manufacturing.
Miguel highlights the strategic importance of the Phoenix, Arizona acquisition, which brings FDA-, EMA-, and PMDA-approved capabilities, OEB5 high-potent handling, and expanded lyophilization capacity. The site also provides invested space for new pre-filled syringe (PFS) lines, giving ROIS a strong foothold in the US market, offering customers shorter lead times and direct regulatory support. Combined with ROIS’s European network, clients now gain a truly global partner for clinical and commercial supply.
Looking ahead, Miguel outlines ROIS’s 2026–2027 expansion roadmap, including full Phoenix integration, the launch of a new Optima PFS isolator line adding 65–70 million PFS units of annual capacity, and expanded device assembly. He emphasizes the critical role of automation and AI-driven systems to accelerate tech transfer, improve quality, and support scalable operations.
The conversation closes with a look at how ROIS is preparing to meet surging demand for GLP-1s and next-generation injectables, with dedicated line designs, Annex 1 compliance, optimized formulation environments, and streamlined tech-transfer processes.
ROIS is positioning itself as a global, end-to-end CDMO partner equipped to take programs from development to commercial supply with speed, reliability, and world-class quality.
Related to this article
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
3
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
4
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
5